Sequenom, Inc.  

(Public, NASDAQ:SQNM)   Watch this stock  
Find more results for SQNM
3.60
-0.04 (-1.10%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.55 - 3.64
52 week 2.02 - 4.19
Open 3.63
Vol / Avg. 1.80M/1.97M
Mkt cap 422.51M
P/E     -
Div/yield     -
EPS -0.42
Shares 117.36M
Beta 0.64
Inst. own 56%
Feb 25, 2015
Q4 2014 Sequenom Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 3, 2014
Sequenom Inc at Piper Jaffray Healthcare Conference
Nov 4, 2014
Q3 2014 Sequenom Inc Earnings Call
Nov 4, 2014
Q3 2014 Sequenom Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -16.02% -66.13%
Operating margin -15.92% -60.59%
EBITD margin - -47.56%
Return on average assets -18.32% -54.57%
Return on average equity - -14282.71%
Employees 570 -
CDP Score - -

Address

3595 John Hopkins Court
SAN DIEGO, CA 92121-1331
United States - Map
+1-858-2029000 (Phone)
+1-858-2029001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sequenom, Inc. (Sequenom) is a molecular diagnostic testing and genetics analysis company committed to providing molecular diagnostic testing services, and research use only products, services, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock, and other areas of research. The Company�s development and commercialization efforts in various diagnostic areas include noninvasive women�s health-related and prenatal diagnostics, ophthalmology, and other medical conditions, such as oncology, infectious diseases and autoimmunity. The Company operates in two segments: Molecular Diagnostics (including Sequenom Center for Molecular Medicine, LLC, or Sequenom CMM) and Genetic Analysis. In May 2014, Sequenom Inc completed the sale of its Bioscience business to Agena Bioscience.

Officers and directors

Harry F. Hixson Jr., Ph.D. Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
William J. Welch President, Chief Executive Officer, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Carolyn D. Beaver Chief Financial Officer, Chief Accounting Officer, Vice President
Age: 56
Bio & Compensation  - Reuters
R. William Bowen Senior Vice President, General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Michael Monko Senior Vice President - Bioscience
Age: 54
Bio & Compensation  - Reuters
Robin G. Weiner Senior Vice President - Quality and Regulatory Affairs
Age: 58
Bio & Compensation  - Reuters
Dirk van den Boom Ph.D. Chief Scientific & Strategy Officer
Age: 43
Bio & Compensation  - Reuters
Richard A. Lerner M.D. Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Myla P. Lai-Goldman M.D. Director
Age: 56
Bio & Compensation  - Reuters
Ronald M. Lindsay Ph.D. Director
Age: 66
Bio & Compensation  - Reuters